INIS
proteins
100%
metastases
85%
cancer
69%
tumors
42%
receptors
39%
bladder
36%
genes
35%
kinases
34%
myosin
33%
chains
28%
interactions
26%
control
21%
tyrosine
21%
phosphorylation
19%
in vitro
16%
in vivo
16%
levels
16%
humans
15%
data
14%
regulations
14%
growth factors
14%
adhesion
14%
tumor cells
12%
antigens
12%
chemotherapy
12%
neurons
12%
migration
12%
carcinomas
11%
apoptosis
11%
mutants
10%
growth
10%
filaments
10%
drugs
9%
inhibition
9%
muscles
9%
phenotype
9%
therapy
8%
cell cycle
8%
molecules
8%
values
8%
affinity
8%
patients
8%
dna damages
7%
tam
7%
rats
7%
promoters
7%
genetics
7%
kinetics
7%
transcription factors
7%
calcium
6%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
37%
S100A4
33%
Cadherin
25%
Mesenchymal-Epithelial Transition
25%
Cell Motility
19%
Receptor Tyrosine Kinase
17%
Mouse
15%
Cell Migration
14%
Heavy Meromyosin
14%
Cell Adhesion
13%
Epidermal Growth Factor Receptor
12%
Transfection
9%
Binding Protein
9%
ZEB1
8%
Preclinical Study
8%
S-100 Protein
8%
DNA Damage
8%
Transcription
8%
Cell Proliferation
7%
Upregulation
7%
Signal Transduction
7%
Drug Resistance
7%
Heavy Chain
7%
Ectodomain
6%
Gene Control
6%
Lapatinib
6%
C-Fos
6%
Transcription Factor Fra 1
6%
Western Blot
6%
Explant
6%
Promoter Region
6%
Antisense
6%
T Cell
6%
Macrophage
6%
Cellular, Subcellular and Molecular Biological Phenomena and Functions
6%
Enhancer Region
6%
Eicosanoid Receptor
6%
Protein Kinase C
6%
Binding Kinetics
6%
G1/S Transition
6%
P53
6%
Virus Recombinant
6%
Enterobacteria Phage T7
6%
STAT1
6%
Genetics
5%
Keyphrases
Epithelial-mesenchymal Transition
19%
S100A4
14%
Mts1
13%
Bladder Cancer Cells
12%
MTA1
12%
New Targets
12%
Receptor Tyrosine Kinase
12%
Metastasis
11%
AXL Inhibitor
10%
In Cancer
8%
TAM Receptors
8%
S100A4 Protein
8%
Tumor Protein p53 (TP53)
7%
Drug Resistance
7%
Cancer Cells
7%
Interacting Proteins
7%
Liprin
7%
E-cadherin
7%
Zinc Finger E-box Binding Homeobox 1 (ZEB1)
6%
Bladder Cancer
6%
SIP1
6%
Cell Migration
6%
Motility
6%
Cancer Metastasis
6%
Tumor Metastasis
6%
FOS-like Antigen 1
6%
Lapatinib
6%
Dual Inhibitor
6%
Leukocyte Common Antigen
6%
Functional Consequences
6%
ErbB1
6%
Transmembrane
6%
Cyclin D1 (CCND1)
6%
C-Fos
6%
Combination Chemotherapy
6%
Normal Function
6%
Protein Tyrosine Phosphatase 1B (PTP1B)
6%
Artesunate
6%
TP-0903
6%
Cancer Drugs
6%
Triple-negative Breast Cancer Cells
6%
Cell Cycle Progression
6%
2 Receptor
6%
Antimalarial Drugs
6%
Chemotherapy Regimen
6%
Dimer Interface
6%
STAT Signaling
6%
Diindolylmethane
6%
Cultured Hippocampal Neurons
6%
Oligomeric Forms
6%
